Cas:100900-16-1 1,4-Chrysenequinone manufacturer & supplier

We serve Chemical Name:1,4-Chrysenequinone CAS:100900-16-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1,4-Chrysenequinone

Chemical Name:1,4-Chrysenequinone
CAS.NO:100900-16-1
Synonyms:1,4-CHRYSENEQUINONE;Chrysene-1,4-dione;Chrysene-1,4-quinone;1,4-Chrysenedione
Molecular Formula:C18H10O2
Molecular Weight:258.271
HS Code:2914399090

Physical and Chemical Properties:
Melting point:210-212ºC(lit.)
Boiling point:499.5±45.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.761
PSA:34.14000
Exact Mass:258.068085
LogP:4.25

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1,4-CHRYSENEQUINONE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,4-Chrysenedione physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Chrysene-1,4-quinone Use and application,Chrysene-1,4-dione technical grade,usp/ep/jp grade.


Related News: Slow business: Due to fear — and travel warnings — fewer people want to travel to China. 1,4-Chrysenequinone manufacturer The increase in environmental protection pressure has also increased the environmental protection expenditure of pharmaceutical manufacturing companies, which forced some small production capacity to withdraw from the market, increased industry concentration, and brought certain opportunities for API manufacturers. 1,4-Chrysenequinone supplier Slow business: Due to fear — and travel warnings — fewer people want to travel to China. 1,4-Chrysenequinone vendor Production of J&J’s vaccine at the Baltimore site was halted by U.S. authorities in April and J&J was put in charge of manufacturing at the plant. 1,4-Chrysenequinone factory The increase in environmental protection pressure has also increased the environmental protection expenditure of pharmaceutical manufacturing companies, which forced some small production capacity to withdraw from the market, increased industry concentration, and brought certain opportunities for API manufacturers.